The global vaccine
CDMO market is set to witness a growth rate of 8% in the next
5 years. Increasing demand for vaccines, rising biopharma and
government partnerships with CDMOs, advancements in vaccine manufacturing
technologies, growing need for specialized CDMO services for new vaccine
technologies, increasing private and public investments in vaccine CDMOs, and
increasing outsourcing trend to reduce costs and accelerate time-to-market are
some of the key factors driving the vaccine CDMO market.
A vaccine contract development and manufacturing
organization (CDMO) provides outsourced services for the development,
manufacturing, and commercialization of vaccines. These organizations support
pharmaceutical and biotech companies by offering end-to-end solutions,
including process development, drug substance production, fill-finish,
packaging, and regulatory compliance. Vaccine CDMOs specialize in advanced
platforms such as mRNA, viral vectors, recombinant proteins, and inactivated
vaccines, helping clients scale up production efficiently. They play a critical
role in accelerating vaccine development, particularly during pandemics, by
offering flexible, high-capacity manufacturing.
🔗 Want deeper insights?
Download the sample report:
https://meditechinsights.com/vaccine-cdmo-market/request-sample/
Increasing demand for vaccines to propel market demand
The rising demand for vaccines, driven by infectious disease
outbreaks, expanding immunization programs, and mRNA vaccine advancements, is
accelerating growth in the vaccine CDMO market. Biopharma companies
increasingly outsource manufacturing to CDMOs to scale production, reduce
costs, and meet stringent regulatory requirements. The success of COVID-19 mRNA
vaccines has fueled demand for CDMOs specializing in lipid nanoparticle
(LNP) formulation and cold chain logistics. Additionally, global
vaccine initiatives and government partnerships are securing long-term
contracts for CDMOs. This trend is pushing major players to expand
manufacturing capacities to meet growing vaccine needs worldwide.
Advancements in vaccine manufacturing technologies are
driving the market growth
Advancements in vaccine manufacturing
technologies, such as mRNA, viral vectors, cell-based production, and single-use
bioreactors, are driving the Vaccine CDMO market. These innovations require
specialized expertise and infrastructure, prompting biopharma companies to
outsource production to CDMOs with advanced capabilities. mRNA vaccine
breakthroughs, particularly in LNP formulation and enzymatic synthesis, have
increased demand for CDMO services. Additionally, automation, continuous
manufacturing, and AI-driven process optimization are enhancing production
efficiency. Leading CDMOs are focusing on next-generation vaccine development,
accelerating global vaccine availability and commercialization.
Competitive Landscape Analysis
The global vaccine CDMO market is marked by the presence of
established and emerging market players such as Lonza Group, Thermo
Fisher Scientific, Catalent, Inc, Samsung Biologics, CordenPharma, WuXi
Vaccines, Recipharm AB, ICON plc, FUJIFILM Diosynth Biotechnologies, and Curia
Global, Inc.; among others. Some of the key strategies adopted by
market players include new product development, strategic partnerships and
collaborations, and geographic expansion.
Gain a competitive edge-request a sample report now!
https://meditechinsights.com/vaccine-cdmo-market/request-sample/
Global Vaccine CDMO Market Segmentation
This report by Medi-Tech Insights provides
the size of the global vaccine CDMO market at the regional- and
country-level from 2023 to 2030. The report further segments the market based
on vaccine type, phase, end user.
Market Size & Forecast (2023-2030), By Vaccine Type,
USD Million
- mRNA
Vaccines
- Viral
Vector Vaccines
- Recombinant
Protein Vaccines
- Inactivated
& Live-Attenuated Vaccines
- Conjugate
& Toxoid Vaccines
- DNA
Vaccines
- Others
Market Size & Forecast (2023-2030), By Phase, USD
Million
- Pre-clinical
- Clinical
- Commercial
Market Size & Forecast (2023-2030), By End User, USD
Million
- Biopharmaceutical
& Vaccine Developers
- Government
& Public Health Agencies
- Others
Market Size & Forecast (2023-2030), By Region, USD
Million
- North
America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest
of Europe
- Asia
Pacific
- China
- India
- Japan
- Rest
of Asia Pacific
- Latin
America
- Middle
East & Africa
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research
& insights firm. Our clients include Fortune 500 companies, blue-chip
investors & hyper-growth start-ups. We have completed 100+ projects in
Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma
Services in the areas of market assessments, due diligence, competitive
intelligence, market sizing and forecasting, pricing analysis &
go-to-market strategy. Our methodology includes rigorous secondary research
combined with deep-dive interviews with industry-leading CXO, VPs, and key
demand/supply side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
Comments
Post a Comment